Eton Pharmaceuticals(ETON)
![icon](https://files.reportify.cn/fe-static/_next/static/media/search.b3fd6117.png?imageMogr2/quality/75/thumbnail/64x/format/webp)
Search documents
Eton Pharmaceuticals(ETON) - 2023 Q4 - Annual Results
2024-03-13 16:00
Exhibit 99.1 Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results ● Q4 2023 revenue of $7.3 million, representing a 109% increase from Q4 2022, marking the twelfth consecutive quarter of sequential product sales growth ● Full year 2023 revenues reached $31.6 million with product sales and royalty revenues of $26.1 million, a 132% increase from 2022 ● Announced successful results from ET-400’s pivotal bioequivalence study, NDA submission planned for Q2 2024 ● Management to hold co ...
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024
Newsfilter· 2024-02-29 21:01
DEER PARK, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2023 financial results on Thursday, March 14, 2024. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT). Register* (Audio Only) Click here In addition to ...
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024
GlobeNewsWire· 2024-02-29 21:01
DEER PARK, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2023 financial results on Thursday, March 14, 2024. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT). Register* (Audio Only) Click here In addition t ...
Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation
Newsfilter· 2024-02-21 11:50
DEER PARK, Ill., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the United States Patent and Trademark Office ("USPTO") has granted the Company's U.S. Patent Application No. 18/113,458, which covers the Company's ET-400 product candidate's proprietary formulation of oral liquid hydrocortisone. The patent has an expiration in 2043 a ...
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
Newsfilter· 2024-02-02 11:50
-- Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* ---- Current Nitisinone market is estimated to exceed $50 million annually ---- Product is now available exclusively through Optime Care -- DEER PARK, Ill., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare disea ...
Eton Pharmaceuticals(ETON) - 2023 Q3 - Earnings Call Transcript
2023-11-09 22:18
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer Conference Call Participants Raghuram Selvaraju - H.C. Wainwright Operator Good afternoon, and welcome to the Eton Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please be advised that this call is being recorded at the com ...
Eton Pharmaceuticals(ETON) - 2023 Q3 - Quarterly Report
2023-11-08 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-38738 ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its ch ...
Eton Pharmaceuticals(ETON) - 2023 Q2 - Earnings Call Transcript
2023-08-11 00:32
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - CEO James Gruber - CFO Conference Call Participants Raghuram Selvaraju - H.C. Wainwright Operator Good afternoon, and welcome to Eton Pharmaceuticals Second Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please be advised that this call is being recorded at the company's request. At this time, I would like t ...
Eton Pharmaceuticals(ETON) - 2023 Q2 - Quarterly Report
2023-08-09 16:00
UNITED STATES- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-38738 ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charte ...
Eton Pharmaceuticals(ETON) - 2023 Q1 - Earnings Call Transcript
2023-05-11 23:04
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q1 2023 Earnings Conference Call May 12, 2023 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - CEO James Gruber - CFO Conference Call Participants Raghuram Selvaraju - H.C. Wainwright & Co Operator Good afternoon and welcome to the Eton Pharmaceuticals' First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen only mode. Following the formal remarks, we will open the call up for your qu ...